Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

OCT Angiography and NRAI in Dementia

NCT03761381 · View on ClinicalTrials.gov ↗

Study Summary

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.

Interventions

  • DEVICE Optical Coherence Tomography Angiography (OCTA) Imaging
  • DEVICE Noninvasive Retinal Amyloid Imaging (NRAI)

Study Locations (1)

Oregon

  • Oregon Health & Science University — Portland

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-09-14
Est. Completion 2027-12

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03761381

The ClinicalTrials.gov registry entry for NCT03761381 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 665 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions — of which Optical Coherence Tomography Angiography (OCTA) Imaging is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03761381 reports 1 study location spanning 1 distinct geographic area — top geographies include Oregon. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03761381 about?

NCT03761381 is a clinical study titled "OCT Angiography and NRAI in Dementia". The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.

What is the current status of trial NCT03761381?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2018-09-14. Estimated completion is 2027-12.

What conditions does trial NCT03761381 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03761381?

The interventions under investigation include: Optical Coherence Tomography Angiography (OCTA) Imaging (DEVICE), Noninvasive Retinal Amyloid Imaging (NRAI) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03761381?

This trial is sponsored by Oregon Health and Science University, which has 665 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03761381 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial